HBIO
Harvard Bioscience, Inc.
Price Chart
Latest Quote
$6.10
+0.09 (+1.50%)
Current Price
| Previous Close | $6.01 |
| Open | $5.97 |
| Day High | $6.13 |
| Day Low | $5.95 |
| Volume | 12,687 |
Stock Information
| Shares Outstanding | 4.51M |
| Total Debt | $44.12M |
| Cash Equivalents | $7.10M |
| Revenue | $85.53M |
| Net Income | $-9.78M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $27.51M |
| EPS (TTM) | $-2.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $64.13M |
| Sales | $85.53M |
| Income | $-9.78M |
| Book/sh | $2.23 |
| Cash/sh | $1.57 |
| Employees | 316 |
Financial Ratios
| Quick Ratio | 0.91 |
| Current Ratio | 1.99 |
| Debt/Eq | 439.20 |
Returns & Margins
| ROA | 1.73% |
| ROE | -78.65% |
| Gross Margin | 58.42% |
| Operating Margin | -4.52% |
| Profit Margin | -11.44% |
Ownership
| Insider Ownership | 9.48% |
| Institutional Ownership | 45.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.86 |
| PEG | 1.31 |
| P/S | 0.32 |
| P/B | 2.74 |
Analyst Data
| Recommendation | none |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $6.13 |
| SMA50 | $6.12 |
| SMA200 | $5.72 |
| RSI | 41.38 |
| ATR | 0.3736 |
| Shares Float | 3.53M |
| Short Float | 2.39% |
| Short Ratio | 3.42 |
| Volatility | 1.51 |
| Rel Volume | 0.53 |
Performance History
| Week | +2.52% |
| Month | +9.13% |
| Quarter | +18.91% |
| 6 Months | -18.67% |
| YTD | -6.15% |
| Year | +19.61% |
| 3 Years | -88.68% |
| 5 Years | -92.10% |
| 10 Years | -80.88% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $6.10 | 12,687 |
| 2026-06-23 | $6.01 | 9,000 |
| 2026-06-22 | $6.06 | 17,900 |
| 2026-06-18 | $5.87 | 21,000 |
| 2026-06-17 | $6.00 | 8,500 |
| 2026-06-16 | $5.95 | 48,400 |
| 2026-06-15 | $5.99 | 28,500 |
| 2026-06-12 | $6.08 | 30,500 |
| 2026-06-11 | $6.64 | 35,400 |
| 2026-06-10 | $6.20 | 11,700 |
| 2026-06-09 | $6.04 | 16,600 |
| 2026-06-08 | $6.01 | 10,600 |
| 2026-06-05 | $6.20 | 8,900 |
| 2026-06-04 | $6.48 | 14,800 |
| 2026-06-03 | $6.50 | 28,600 |
| 2026-06-02 | $6.46 | 29,000 |
| 2026-06-01 | $6.40 | 75,000 |
| 2026-05-29 | $5.88 | 12,000 |
| 2026-05-28 | $5.95 | 40,600 |
| 2026-05-27 | $5.78 | 21,400 |
| 2026-05-26 | $5.68 | 30,800 |
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
đ° Latest News
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...
GuruFocus.com âĸ 2026-05-12T19:01:29ZHarvard Bioscience, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-12T17:08:24Z
How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 Expectations
Simply Wall St. âĸ 2026-03-16T03:10:13Z
Harvard Bioscience Inc (HBIO) Q4 2025 Earnings Call Highlights: Strong Operational Efficiency ...
GuruFocus.com âĸ 2026-03-12T19:01:42ZHarvard Bioscience, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-12T16:58:42Z
Harvard Bioscience (HBIO) Earnings Transcript
Motley Fool âĸ 2026-03-12T14:19:43Z
Harvard Bioscience: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-12T11:47:10ZHarvard Bioscience will move Holliston MA manufacturing out of state
The Metrowest Daily News âĸ 2026-02-03T10:35:03Z
Analysts Have Been Trimming Their Harvard Bioscience, Inc. (NASDAQ:HBIO) Price Target After Its Latest Report
Simply Wall St. âĸ 2025-11-09T13:30:28Z
Is It Time To Consider Buying Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Simply Wall St. âĸ 2025-11-07T11:08:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $34,722,000 | $37,467,000 | $44,706,000 | $51,063,000 |
| Cost Of Revenue | $36,640,000 | $39,369,000 | $46,179,000 | $52,516,000 |
| Total Revenue | $86,550,000 | $94,135,000 | $112,250,000 | $113,335,000 |
| Operating Revenue | $86,550,000 | $94,135,000 | $112,250,000 | $113,335,000 |
| Expenses | ||||
| Interest Expense | $4,917,000 | $3,536,000 | $3,591,000 | $2,548,000 |
| Total Expenses | $86,450,000 | $100,346,000 | $110,356,000 | $120,501,000 |
| Other Income Expense | $-52,569,000 | $-1,918,000 | $-859,000 | $535,000 |
| Other Non Operating Income Expenses | $-3,889,000 | $-325,000 | $-227,000 | $302,000 |
| Net Non Operating Interest Income Expense | $-4,917,000 | $-3,536,000 | $-3,591,000 | $-2,548,000 |
| Interest Expense Non Operating | $4,917,000 | $3,536,000 | $3,591,000 | $2,548,000 |
| Operating Expense | $49,810,000 | $60,977,000 | $64,177,000 | $67,985,000 |
| Selling And Marketing Expense | $19,216,000 | $22,212,000 | $24,060,000 | $25,041,000 |
| General And Administrative Expense | $17,742,000 | $21,493,000 | $22,757,000 | $24,493,000 |
| Other Operating Expenses | - | $1,611,000 | $71,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Net Interest Income | $-4,917,000 | $-3,536,000 | $-3,591,000 | $-2,548,000 |
| Normalized Income | $-8,555,480 | $-11,146,530 | $-2,915,720 | $-9,700,070 |
| Net Income From Continuing And Discontinued Operation | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Total Operating Income As Reported | $-48,580,000 | $-6,211,000 | $1,894,000 | $-6,933,000 |
| Net Income Common Stockholders | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Net Income | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Net Income Including Noncontrolling Interests | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Net Income Continuous Operations | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Pretax Income | $-57,386,000 | $-11,665,000 | $-2,556,000 | $-9,179,000 |
| Special Income Charges | $-48,680,000 | $0 | $0 | $233,000 |
| Operating Income | $100,000 | $-6,211,000 | $1,894,000 | $-7,166,000 |
| Depreciation Amortization Depletion Income Statement | $4,027,000 | $5,255,000 | $5,525,000 | $6,122,000 |
| Depreciation And Amortization In Income Statement | $4,027,000 | $5,255,000 | $5,525,000 | $6,122,000 |
| Amortization Of Intangibles Income Statement | $4,027,000 | $5,255,000 | $5,525,000 | $6,122,000 |
| Gross Profit | $49,910,000 | $54,766,000 | $66,071,000 | $60,819,000 |
| Per Share | ||||
| Diluted EPS | $-12.80 | $-2.80 | $-0.80 | $-2.30 |
| Basic EPS | $-12.80 | $-2.80 | $-0.80 | $-2.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $-535,480 | $-334,530 | $-132,720 | $48,930 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $2,156,000 | $621,000 | $8,665,000 | $711,000 |
| Total Unusual Items | $-48,680,000 | $-1,593,000 | $-632,000 | $233,000 |
| Total Unusual Items Excluding Goodwill | $-48,680,000 | $-1,593,000 | $-632,000 | $233,000 |
| Reconciled Depreciation | $5,945,000 | $7,157,000 | $6,998,000 | $7,575,000 |
| EBITDA (Bullshit earnings) | $-46,524,000 | $-972,000 | $8,033,000 | $944,000 |
| EBIT | $-52,469,000 | $-8,129,000 | $1,035,000 | $-6,631,000 |
| Diluted Average Shares | $4,439,100 | $4,353,800 | $4,242,000 | $4,141,300 |
| Basic Average Shares | $4,439,100 | $4,353,800 | $4,242,000 | $4,141,300 |
| Diluted NI Availto Com Stockholders | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Tax Provision | $-686,000 | $740,000 | $859,000 | $337,000 |
| Other Special Charges | $541,000 | - | - | $-233,000 |
| Impairment Of Capital Assets | $47,951,000 | $0 | - | - |
| Restructuring And Mergern Acquisition | $188,000 | - | - | - |
| Amortization | $4,027,000 | $5,255,000 | $5,525,000 | $6,122,000 |
| Research And Development | $8,825,000 | $10,406,000 | $11,764,000 | $12,329,000 |
| Selling General And Administration | $36,958,000 | $43,705,000 | $46,817,000 | $49,534,000 |
| Other Gand A | $17,742,000 | $21,493,000 | $22,757,000 | $24,493,000 |
| Gain On Sale Of Security | - | $-1,593,000 | $-632,000 | - |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-3,464,000 | $-4,116,000 | $-27,000 | $-5,054,000 |
| Total Assets | $80,071,000 | $126,644,000 | $137,366,000 | $145,360,000 |
| Total Non Current Assets | $31,846,000 | $81,527,000 | $88,328,000 | $94,236,000 |
| Other Non Current Assets | $2,689,000 | $2,833,000 | $6,473,000 | $7,780,000 |
| Goodwill And Other Intangible Assets | $17,198,000 | $67,456,000 | $73,101,000 | $77,274,000 |
| Other Intangible Assets | $7,639,000 | $11,132,000 | $16,036,000 | $21,014,000 |
| Current Assets | $48,225,000 | $45,117,000 | $49,038,000 | $51,124,000 |
| Other Current Assets | $2,763,000 | $2,898,000 | $3,940,000 | $3,472,000 |
| Inventory | $20,805,000 | $23,245,000 | $24,716,000 | $26,439,000 |
| Receivables | $16,043,000 | $14,866,000 | $16,099,000 | $16,705,000 |
| Accounts Receivable | $16,043,000 | $14,866,000 | $16,099,000 | $16,705,000 |
| Allowance For Doubtful Accounts Receivable | $-207,000 | $-215,000 | $-160,000 | $-191,000 |
| Gross Accounts Receivable | $16,250,000 | $15,081,000 | $16,259,000 | $16,896,000 |
| Cash Cash Equivalents And Short Term Investments | $8,614,000 | $4,108,000 | $4,283,000 | $4,508,000 |
| Cash And Cash Equivalents | $8,614,000 | $4,108,000 | $4,283,000 | $4,508,000 |
| Debt | ||||
| Net Debt | $27,256,000 | $32,848,000 | $32,280,000 | $42,316,000 |
| Total Debt | $44,277,000 | $44,495,000 | $42,773,000 | $54,241,000 |
| Long Term Debt And Capital Lease Obligation | $42,752,000 | $6,381,000 | $35,498,000 | $48,295,000 |
| Long Term Debt | $35,870,000 | - | $30,704,000 | $43,013,000 |
| Current Debt And Capital Lease Obligation | $1,525,000 | $38,114,000 | $7,275,000 | $5,946,000 |
| Current Debt | - | $36,956,000 | $5,859,000 | $3,811,000 |
| Other Current Borrowings | - | $36,956,000 | $5,859,000 | $3,811,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $66,337,000 | $63,304,000 | $64,292,000 | $73,140,000 |
| Total Non Current Liabilities Net Minority Interest | $44,377,000 | $8,346,000 | $37,750,000 | $49,891,000 |
| Other Non Current Liabilities | $1,308,000 | $1,255,000 | $1,476,000 | $1,006,000 |
| Non Current Deferred Liabilities | $317,000 | $710,000 | $776,000 | $590,000 |
| Non Current Deferred Taxes Liabilities | $317,000 | $710,000 | $776,000 | $590,000 |
| Current Liabilities | $21,960,000 | $54,958,000 | $26,542,000 | $23,249,000 |
| Other Current Liabilities | $11,521,000 | $6,537,000 | $5,276,000 | $4,010,000 |
| Current Deferred Liabilities | $3,447,000 | $3,806,000 | $4,508,000 | $3,370,000 |
| Payables And Accrued Expenses | $3,652,000 | $4,787,000 | $5,554,000 | $6,447,000 |
| Payables | $3,652,000 | $4,787,000 | $5,554,000 | $6,447,000 |
| Accounts Payable | $3,652,000 | $4,787,000 | $5,554,000 | $6,447,000 |
| Total Tax Payable | - | - | - | $0 |
| Income Tax Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $13,734,000 | $63,340,000 | $73,074,000 | $72,220,000 |
| Total Equity Gross Minority Interest | $13,734,000 | $63,340,000 | $73,074,000 | $72,220,000 |
| Stockholders Equity | $13,734,000 | $63,340,000 | $73,074,000 | $72,220,000 |
| Gains Losses Not Affecting Retained Earnings | $-11,672,000 | $-15,670,000 | $-14,190,000 | $-15,052,000 |
| Other Equity Adjustments | $-11,672,000 | $-15,670,000 | $-14,190,000 | $-15,052,000 |
| Retained Earnings | $-214,710,000 | $-158,010,000 | $-145,605,000 | $-142,190,000 |
| Other | ||||
| Ordinary Shares Number | $4,471,989 | $4,407,447 | $4,339,450 | $4,208,170 |
| Share Issued | $4,471,989 | $4,407,447 | $4,339,450 | $4,208,170 |
| Tangible Book Value | $-3,464,000 | $-4,116,000 | $-27,000 | $-5,054,000 |
| Invested Capital | $49,604,000 | $100,296,000 | $109,637,000 | $119,044,000 |
| Working Capital | $26,265,000 | $-9,841,000 | $22,496,000 | $27,875,000 |
| Capital Lease Obligations | $8,407,000 | $7,539,000 | $6,210,000 | $7,417,000 |
| Total Capitalization | $49,604,000 | $63,340,000 | $103,778,000 | $115,233,000 |
| Additional Paid In Capital | $239,669,000 | $236,579,000 | $232,435,000 | $229,008,000 |
| Capital Stock | $447,000 | $441,000 | $434,000 | $454,000 |
| Common Stock | $447,000 | $441,000 | $434,000 | $454,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $6,882,000 | $6,381,000 | $4,794,000 | $5,282,000 |
| Current Deferred Revenue | $3,447,000 | $3,806,000 | $4,508,000 | $3,370,000 |
| Current Capital Lease Obligation | $1,525,000 | $1,158,000 | $1,416,000 | $2,135,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,815,000 | $1,714,000 | $3,929,000 | $3,476,000 |
| Goodwill | $9,559,000 | $56,324,000 | $57,065,000 | $56,260,000 |
| Net PPE | $11,959,000 | $11,238,000 | $8,754,000 | $9,182,000 |
| Accumulated Depreciation | $-18,116,000 | $-15,820,000 | $-14,385,000 | $-14,846,000 |
| Gross PPE | $30,075,000 | $27,058,000 | $23,139,000 | $24,028,000 |
| Leases | $2,666,000 | $2,565,000 | $2,417,000 | $2,507,000 |
| Other Properties | $7,172,000 | $6,132,000 | $4,773,000 | $5,816,000 |
| Machinery Furniture Equipment | $20,237,000 | $18,361,000 | $15,949,000 | $15,705,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $5,371,000 | $5,222,000 | $5,120,000 | $5,223,000 |
| Work In Process | $3,262,000 | $2,754,000 | $4,188,000 | $3,776,000 |
| Raw Materials | $12,172,000 | $15,269,000 | $15,408,000 | $17,440,000 |
| Treasury Stock | - | - | - | $0 |
| Current Provisions | - | - | - | $268,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $4,866,000 | $-1,823,000 | $11,717,000 | $-438,000 |
| Operating Activities | ||||
| Operating Cash Flow | $6,729,000 | $1,440,000 | $14,028,000 | $1,152,000 |
| Cash Flow From Continuing Operating Activities | $6,729,000 | $1,440,000 | $14,028,000 | $1,152,000 |
| Operating Gains Losses | $1,363,000 | $1,593,000 | $229,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,863,000 | $-3,263,000 | $-2,311,000 | $-1,590,000 |
| Investing Cash Flow | $-1,863,000 | $-1,344,000 | $-1,799,000 | $-1,590,000 |
| Cash Flow From Continuing Investing Activities | $-1,863,000 | $-1,344,000 | $-1,799,000 | $-1,590,000 |
| Capital Expenditure Reported | $-605,000 | $-619,000 | $-523,000 | $0 |
| Financing Activities | ||||
| Financing Cash Flow | $-1,291,000 | $-131,000 | $-12,134,000 | $-2,837,000 |
| Cash Flow From Continuing Financing Activities | $-1,291,000 | $-131,000 | $-12,134,000 | $-2,837,000 |
| Net Other Financing Charges | $-3,988,000 | $-738,000 | $-2,523,000 | $-1,628,000 |
| Other | ||||
| Repayment Of Debt | $-37,350,000 | $-8,573,000 | $-15,041,000 | $-9,586,000 |
| Issuance Of Debt | $40,000,000 | $8,800,000 | $4,500,000 | $7,800,000 |
| Interest Paid Supplemental Data | $3,595,000 | $3,235,000 | $3,795,000 | $2,314,000 |
| End Cash Position | $8,614,000 | $4,108,000 | $4,283,000 | $4,508,000 |
| Beginning Cash Position | $4,108,000 | $4,283,000 | $4,508,000 | $7,821,000 |
| Effect Of Exchange Rate Changes | $931,000 | $-140,000 | $-320,000 | $-38,000 |
| Changes In Cash | $3,575,000 | $-35,000 | $95,000 | $-3,275,000 |
| Proceeds From Stock Option Exercised | $47,000 | $380,000 | $930,000 | $577,000 |
| Net Issuance Payments Of Debt | $2,650,000 | $227,000 | $-10,541,000 | $-1,786,000 |
| Net Long Term Debt Issuance | $2,650,000 | $227,000 | $-10,541,000 | $-1,786,000 |
| Long Term Debt Payments | $-37,350,000 | $-8,573,000 | $-15,041,000 | $-9,586,000 |
| Long Term Debt Issuance | $40,000,000 | $8,800,000 | $4,500,000 | $7,800,000 |
| Net Investment Purchase And Sale | $0 | $1,919,000 | $0 | - |
| Sale Of Investment | $0 | $1,919,000 | $0 | - |
| Net PPE Purchase And Sale | $-1,258,000 | $-2,644,000 | $-1,788,000 | $-1,590,000 |
| Purchase Of PPE | $-1,258,000 | $-2,644,000 | $-1,788,000 | $-1,590,000 |
| Change In Working Capital | $5,673,000 | $65,000 | $4,600,000 | $2,716,000 |
| Change In Other Working Capital | $-161,000 | $-702,000 | $1,138,000 | $-896,000 |
| Change In Other Current Assets | $1,521,000 | $1,642,000 | $1,651,000 | $474,000 |
| Change In Payables And Accrued Expense | $2,300,000 | $-1,785,000 | $-523,000 | $-1,399,000 |
| Change In Payable | $2,300,000 | $-1,785,000 | $-523,000 | $-1,399,000 |
| Change In Account Payable | $2,300,000 | $-1,785,000 | $-523,000 | $-1,399,000 |
| Change In Inventory | $2,947,000 | $-64,000 | $1,524,000 | $252,000 |
| Change In Receivables | $-934,000 | $974,000 | $810,000 | $4,780,000 |
| Changes In Account Receivables | $-934,000 | $974,000 | $810,000 | $4,780,000 |
| Other Non Cash Items | $1,322,000 | $327,000 | $280,000 | $-3,620,000 |
| Stock Based Compensation | $1,855,000 | $4,340,000 | $5,000,000 | $4,411,000 |
| Asset Impairment Charge | $47,951,000 | $0 | - | - |
| Deferred Tax | $-680,000 | $363,000 | $336,000 | $-414,000 |
| Deferred Income Tax | $-680,000 | $363,000 | $336,000 | $-414,000 |
| Depreciation Amortization Depletion | $5,945,000 | $7,157,000 | $6,998,000 | $7,575,000 |
| Depreciation And Amortization | $5,945,000 | $7,157,000 | $6,998,000 | $7,575,000 |
| Amortization Cash Flow | $4,202,000 | $5,430,000 | $5,525,000 | $6,122,000 |
| Amortization Of Intangibles | $4,202,000 | $5,430,000 | $5,525,000 | $6,122,000 |
| Depreciation | $1,743,000 | $1,727,000 | $1,473,000 | $1,453,000 |
| Pension And Employee Benefit Expense | $1,233,000 | $0 | - | - |
| Net Income From Continuing Operations | $-56,700,000 | $-12,405,000 | $-3,415,000 | $-9,516,000 |
| Net Business Purchase And Sale | - | $0 | $512,000 | $0 |
| Sale Of Business | - | $0 | $512,000 | $0 |
| Gain Loss On Investment Securities | - | $1,593,000 | $632,000 | - |
| Gain Loss On Sale Of Business | - | $0 | $-403,000 | $0 |
| Income Tax Paid Supplemental Data | - | - | $207,000 | $534,000 |
| Change In Other Current Liabilities | - | - | $-1,078,000 | $-495,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $632,000 | $0 |
| Net Short Term Debt Issuance | - | - | - | $1,400,000 |
| Short Term Debt Payments | - | - | - | $-6,400,000 |
| Short Term Debt Issuance | - | - | - | $7,800,000 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
Fetched: 2026-06-24